Francis P. Worden, MD, discusses how the effectiveness of lenvatinib in this real-world setting compares with results from ...
The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with ...
Sonodynamic therapy doubled the median overall survival to 15.7 months and tripled progression-free survival to 5.5 months in ...
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the CEPHEUS trial results and impact on frontline treatment in ...
The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.
During a Case-Based Roundtable meeting, Lipson and participants talked about the complexity of choosing the right therapy for ...
Enrollment in cohort 5 of the phase 1/2 GOBLET study will resume after the Data Safety Monitoring Board’s safety review.